A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer

British Journal of Cancer

Volumn 92, Issue 9, 2005, Pages 1655-1662

  Schippinger, W ^a,g   Jagoditsch, M ^b   Sorre C ^b   Gnant, M ^c   Steger, G ^c   Hausmaninger, H ^d   Mlineritsch, B ^d   Schaberl Moser, R ^a   Mischinger, H J ^a   Hofbauer, F ^e   Holzberger, P ^f   Mittlbock M ^c   Jakesz, R ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b St Veit Hospital   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e Oberpullendorf Hospital   (Austria)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Adjuvant therapy; Colon cancer; Interferon; Levamisole

Indexed keywords

ALPHA2A INTERFERON; BEROFOR; FLUOROURACIL; LEVAMISOLE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LEUCOVORIN; LEVAMISOLE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 19944393210     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602555     Document Type: Article

References (23)

1. Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R, on behalf of the Arbeitsgemeinschaft Gastrointestinale Onkologie (2003) 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol 14: 395-399
2. Arnaud JP, Buyse M, Nordlinger B, Martin F, Pector JC, Zeitoun P, Adloff A, Duez N (1989) Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg 76: 284-289
3. Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA, Moon MD (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3: 1624-1631
4. Cox DR (1972) Regression models and life-tables. J R Stat Soc [B] 34: 187-220
5. Dencausse Y, Hartung G, Sturm J, Kopp-Schneider A, Hagmuller E, Wojatschek C, Lindemann H, Fritze D, Queisser W (2002) Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 25: 426-430
6. Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A, Lionetto R, Bruzzi P, Luppi G, Gallo L, Conte P, Comandone A, Turci D, Marzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M, Rosso R, on behalf of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC (2003) Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol 14: 1365-1372
7. Haller DG, Catalano PJ, Mac Donald JS (1998) Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 17: 256 (abstract 982)
8. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
9. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil - The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447-1456
10. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
11. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Click JH, Veeder MH, Maillard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
12. NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450
13. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66
14. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115
15. QUASAR Collaborative Group (2000) Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 355: 1588-1596
16. Sertoli MR, Guarneri D, Rubagotti A, Porcile G, Nobile MT, Rosso R (1987) Adjuvant immunochemotherapy in colorectal cancer Dukes C. Oncology 44: 78-81
17. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N (1991) Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 9: 1806-1810
18. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769-1775
19. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50: 5735-5739
20. Wiebke EA, Grieshop NA, Loehrer PJ, Eckert GJ, Sidner RA (2003) Antitumor effects of 5-fluorouracil on human colon cancer cell lines: antagonism by levamisole. J Surg Res 111: 63-69
21. Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, Fisher B (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90: 1810-1816
22. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80: 30-36
23. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17: 3553-3559